These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16448844)

  • 21. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
    Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
    Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alphaviruses in cancer immunotherapy.
    Lundstrom K
    Int Rev Cell Mol Biol; 2023; 379():143-168. PubMed ID: 37541722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical development of MVA-based therapeutic cancer vaccines.
    Acres B; Bonnefoy JY
    Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alphaviruses in gene therapy.
    Lundstrom K
    Viruses; 2015 May; 7(5):2321-33. PubMed ID: 25961488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant viral vectors: cancer vaccines.
    Harrop R; John J; Carroll MW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
    de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
    Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mimotope vaccines for cancer immunotherapy.
    Sharav T; Wiesmüller KH; Walden P
    Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alphavirus-Based Vaccines.
    Lundstrom K
    Methods Mol Biol; 2016; 1404():313-328. PubMed ID: 27076308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.
    Osada T; Morse MA; Hobeika A; Lyerly HK
    Semin Oncol; 2012 Jun; 39(3):305-10. PubMed ID: 22595053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alphavirus vectors: applications for DNA vaccine production and gene expression.
    Lundstrom K
    Intervirology; 2000; 43(4-6):247-57. PubMed ID: 11251380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alphaviral cytotoxicity and its implication in vector development.
    Rhême C; Ehrengruber MU; Grandgirard D
    Exp Physiol; 2005 Jan; 90(1):45-52. PubMed ID: 15542620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promising particle-based vaccines in cancer therapy.
    Xiang SD; Scalzo-Inguanti K; Minigo G; Park A; Hardy CL; Plebanski M
    Expert Rev Vaccines; 2008 Sep; 7(7):1103-19. PubMed ID: 18767957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
    Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
    J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen.
    Ali S; Mulryan K; Taher T; Stern PL
    Cancer Immunol Immunother; 2007 Feb; 56(2):165-80. PubMed ID: 16758205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.